CA2347835A1 - Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque - Google Patents

Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque Download PDF

Info

Publication number
CA2347835A1
CA2347835A1 CA002347835A CA2347835A CA2347835A1 CA 2347835 A1 CA2347835 A1 CA 2347835A1 CA 002347835 A CA002347835 A CA 002347835A CA 2347835 A CA2347835 A CA 2347835A CA 2347835 A1 CA2347835 A1 CA 2347835A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
mammal
pro179
pro713
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002347835A
Other languages
English (en)
Inventor
Avi J. Ashkenazi
Kevin P. Baker
Napoleone Ferrara
Hanspeter Gerber
Kenneth J. Hillan
Audrey Goddard
Paul J. Godowski
Austin L. Gurney
Robert D. Klein
Sophia S. Kuo
Nicholas F. Paoni
Victoria Smith
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1998/025108 external-priority patent/WO1999028462A2/fr
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/fr
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/fr
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/fr
Priority claimed from PCT/US1999/020594 external-priority patent/WO2000015666A2/fr
Priority claimed from PCT/US1999/020944 external-priority patent/WO2000015792A2/fr
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/fr
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/fr
Priority claimed from PCT/US1999/023089 external-priority patent/WO2000021996A2/fr
Priority to CA002503475A priority Critical patent/CA2503475A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2347835A1 publication Critical patent/CA2347835A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)

Abstract

La présente invention concerne des compositions et des procédés permettant de stimuler et d'inhiber l'angiogenèse et la vascularisation cardiaque des mammifères, y-compris des humains. Ces compositions sont à base de polypeptides, ou d'antagonistes de ces polypeptides, identifiés par rapport à l'une ou l'autre des utilisations considérées. Les troubles qu'envisagent de diagnostiquer, de prévenir ou de traiter ces compositions sont essentiellement des traumatismes tels que les blessures, divers cancers, et des troubles affectant les vaisseaux sanguins tels que l'athérosclérose et l'hypertrophie cardiaque. L'invention concerne aussi les polypeptides de l'invention ainsi que des molécules d'acide nucléique codant ces polypeptides. L'invention concerne également des vecteurs et des cellules hôte comprenant ces séquences d'acides nucléiques, des molécules de polypeptides chimériques comprenant les polypeptides de l'invention fusionnés avec des séquences de polypeptides hétérologues, des anticorps se liant aux polypeptides de l'invention, et des procédés permettant la production des polypeptides de l'invention.
CA002347835A 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque Abandoned CA2347835A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002503475A CA2503475A1 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque

Applications Claiming Priority (37)

Application Number Priority Date Filing Date Title
PCT/US1998/025108 WO1999028462A2 (fr) 1997-12-03 1998-12-01 Polypeptides et acides nucleiques codant ces derniers
USPCT/US98/25108 1998-12-01
US11285098P 1998-12-16 1998-12-16
US60/112,850 1998-12-16
US11555499P 1999-01-12 1999-01-12
US60/115,554 1999-01-12
PCT/US1999/005028 WO1999046281A2 (fr) 1998-03-10 1999-03-08 Nouveaux polypeptides et acides nucleiques les codant
USPCT/US99/05028 1999-03-08
US12395799P 1999-03-12 1999-03-12
US60/123,957 1999-03-12
US13144599P 1999-04-28 1999-04-28
US60/131,445 1999-04-28
US13428799P 1999-05-14 1999-05-14
US60/134,287 1999-05-14
USPCT/US99/12252 1999-06-02
PCT/US1999/012252 WO1999063088A2 (fr) 1998-06-02 1999-06-02 Proteines membranaires et acides nucleiques codant ces proteines
US14103799P 1999-06-23 1999-06-23
US60/141,037 1999-06-23
US14475899P 1999-07-20 1999-07-20
US60/144,758 1999-07-20
US14569899P 1999-07-26 1999-07-26
US60/145,698 1999-07-26
USPCT/US99/20111 1999-09-01
PCT/US1999/020111 WO2000012708A2 (fr) 1998-09-01 1999-09-01 Nouveaux pro-polypeptides et sequences correspondantes
USPCT/US99/20594 1999-09-08
PCT/US1999/020594 WO2000015666A2 (fr) 1998-09-10 1999-09-08 Compositions et methodes de traitement des tumeurs
USPCT/US99/20944 1999-09-13
PCT/US1999/020944 WO2000015792A2 (fr) 1998-09-14 1999-09-13 Promotion ou inhibition d'angiogenese et de cardiovascularisation
USPCT/US99/21547 1999-09-15
PCT/US1999/021090 WO2000015796A2 (fr) 1998-09-16 1999-09-15 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US1999/021547 WO2000015797A2 (fr) 1998-09-17 1999-09-15 Compositions et methodes de traitement des maladies relatives au syteme immunitaire
USPCT/US99/21090 1999-09-15
USPCT/US99/23089 1999-10-05
PCT/US1999/023089 WO2000021996A2 (fr) 1998-10-13 1999-10-05 Procedes et compositions inhibant la croissance des cellules neoplasiques
US16250699P 1999-10-29 1999-10-29
US60/162,506 1999-10-29
PCT/US1999/028313 WO2000032221A2 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002503475A Division CA2503475A1 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque

Publications (1)

Publication Number Publication Date
CA2347835A1 true CA2347835A1 (fr) 2000-06-08

Family

ID=37398593

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002347835A Abandoned CA2347835A1 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque

Country Status (9)

Country Link
EP (1) EP1135485B1 (fr)
JP (3) JP3695642B2 (fr)
KR (1) KR100529270B1 (fr)
AT (1) ATE458050T1 (fr)
AU (1) AU771751C (fr)
CA (1) CA2347835A1 (fr)
IL (1) IL202176A0 (fr)
MX (1) MXPA01005169A (fr)
WO (1) WO2000032221A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053760A2 (fr) * 1999-03-12 2000-09-14 Genentech, Inc. Technique permettant de prevenir la mort des neurones retiniens et traitement des maladies oculaires
EP1007659B1 (fr) 1997-01-14 2007-06-27 Human Genome Sciences, Inc. Recepteurs 6 alpha & 6 beta du facteur de necrose tumorale
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US20030054987A1 (en) * 1997-06-16 2003-03-20 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
IL134578A0 (en) 1997-09-18 2001-04-30 Genentech Inc DcR3 POLYPEPTIDE, A TNFR HOMOLOG
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
AU758353B2 (en) 1998-03-17 2003-03-20 Genentech Inc. Polypeptides homologous to VEGF and BMP1
US6949339B1 (en) 1998-05-21 2005-09-27 Diadexus, Inc. Method of diagnosing, monitoring, and staging colon cancer
CA2331154A1 (fr) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. Polypeptides presentant une sequence distincte comprenant une sous-unite de facteur de croissance insulinomimetique labile en milieu acide
US7014996B1 (en) 1998-10-02 2006-03-21 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers
ES2279647T3 (es) 1998-11-10 2007-08-16 Emory University Reguladores mitogenicos.
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
AU1512900A (en) * 1998-12-09 2000-06-26 Shionogi & Co., Ltd. Human secretory phospholipase a2
AU2486300A (en) * 1998-12-30 2000-07-31 Millennium Pharmaceuticals, Inc. Secreted proteins and nucleic acids encoding them
AU768694B2 (en) * 1999-03-08 2004-01-08 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO2000053776A2 (fr) * 1999-03-11 2000-09-14 Mount Sinai Hospital Nouveaux genes humains du type kallikreine
IL147442A0 (en) * 1999-07-12 2002-08-14 Genentech Inc Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
CA2375458A1 (fr) * 1999-07-20 2001-01-25 Genentech, Inc. Compositions et methodes pour traiter des maladies d'ordre immunologique
AU3902600A (en) * 1999-09-15 2001-04-17 Genentech Inc. Compositions and methods for the treatment of immune related diseases
WO2001042499A1 (fr) * 1999-12-09 2001-06-14 Sankyo Company, Limited Procede d'essai d'agent curatif ou preventif de l'hyperlipemie
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
NZ520065A (en) * 2000-01-12 2006-02-24 Univ Yale Nogo receptor-mediated blockade of axonal growth
AU2001245371A1 (en) 2000-02-28 2001-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
CA2406855A1 (fr) 2000-04-21 2001-11-01 Takeda Chemical Industries, Ltd. Nouveaux polypeptides appartenant a la famille insuline/igf/relaxine et adn correspondants
JP2004516013A (ja) * 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
DK1325130T3 (da) 2000-10-06 2010-05-25 Univ Yale Nogo-Receptorhomologer
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
JPWO2002057448A1 (ja) * 2000-12-27 2004-05-20 第一ファインケミカル株式会社 新規ペプチド及びその活性
CA2443123A1 (fr) 2001-04-10 2002-10-24 Agensys, Inc. Acides nucleiques et proteines correspondantes utiles pour la detection et le traitement de divers cancers
WO2003006687A2 (fr) * 2001-07-10 2003-01-23 Medigene Ag Nouveaux genes cibles concernant des maladies cardiaques
EP1463525B1 (fr) * 2001-12-19 2008-09-17 Genentech, Inc. Compositions et methodes de diagnostic et de traitement de tumeur
US7314866B2 (en) * 2002-03-01 2008-01-01 Bloodcenter Of Wisconsin, Inc. Ku-70-derived Bax-suppressing peptides and use thereof for the protection of damaged cells
WO2003083114A1 (fr) * 2002-03-28 2003-10-09 Yamanouchi Pharmaceutical Co., Ltd. Facteur de croissance associe a une antiopoietine
WO2004002515A1 (fr) * 2002-06-28 2004-01-08 Takeda Chemical Industries, Ltd. Agents diagnostiques/preventifs/curatifs pour maladies respiratoires
EA200500330A1 (ru) 2002-08-10 2006-06-30 Йейл Юниверсити Антагонисты nogo рецепторов
WO2005068497A1 (fr) * 2004-01-06 2005-07-28 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Iis: nouvel proteine inductible par ifn-gamma, element de la famille des secretoglobines, modulant l'invasion et la migration cellulaire
US7893032B2 (en) 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
SG10201810507WA (en) 2014-06-06 2018-12-28 Bristol Myers Squibb Co Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
EA201792497A1 (ru) 2015-06-03 2018-05-31 Бристол-Майерс Сквибб Компани Антитела к gitr для диагностики злокачественной опухоли
WO2017087678A2 (fr) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Anticorps dirigés contre un récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs utilisations
KR20200006115A (ko) 2017-05-16 2020-01-17 브리스톨-마이어스 스큅 컴퍼니 항-gitr 효능제 항체에 의한 암의 치료
CN109136275B (zh) * 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化gitr基因改造动物模型的制备方法及应用
CN114507677B (zh) * 2022-02-16 2023-09-05 中国人民解放军空军军医大学 Ndufs1基因在治疗心梗后心衰中的应用和相关产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
CA2134773A1 (fr) 1992-06-04 1993-12-09 Robert J. Debs Methodes et compositions pour genotherapie in vivo
US5885795A (en) * 1994-04-26 1999-03-23 The Children's Medical Center Corporation Methods of expressing angiostatic protein
US5681746A (en) 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
EP0861894B1 (fr) * 1995-11-17 2006-03-08 Asahi Kasei Kabushiki Kaisha Polypeptide suppresseur et de differenciation

Also Published As

Publication number Publication date
MXPA01005169A (es) 2002-07-02
AU771751B2 (en) 2004-04-01
JP2005046146A (ja) 2005-02-24
AU771751C (en) 2006-04-06
WO2000032221A2 (fr) 2000-06-08
JP2003524385A (ja) 2003-08-19
EP1135485B1 (fr) 2010-02-17
WO2000032221A3 (fr) 2000-11-23
KR20010086070A (ko) 2001-09-07
AU1748200A (en) 2000-06-19
ATE458050T1 (de) 2010-03-15
JP2006006329A (ja) 2006-01-12
JP4358159B2 (ja) 2009-11-04
JP3695642B2 (ja) 2005-09-14
JP3803681B2 (ja) 2006-08-02
IL202176A0 (en) 2010-06-16
EP1135485A2 (fr) 2001-09-26
KR100529270B1 (ko) 2005-11-21

Similar Documents

Publication Publication Date Title
AU771751B2 (en) Promotion or inhibition of angiogenesis and cardiovascularization
EP1309620A2 (fr) Compositions et procedes de diagnose et traitement de maladies faisant intervenir l'angiogenese
WO2002008284A2 (fr) Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
AU768694B2 (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2000053753A2 (fr) Activation ou inhibition de l'angiogenese et de la cardiovascularisation
JP2003531811A5 (fr)
KR100543857B1 (ko) 혈관신생 및 심혈관형성의 촉진 또는 억제
WO2000053752A2 (fr) Activation ou inhibition de l'angiogenese et de la cardiovascularisation
US6800604B2 (en) Polypeptides that inhibit human serum-induced cleavage of hepatocyte growth factor
CA2376116A1 (fr) Promotion ou inhibition de l'angiogenese et de la cardiovascularisation
WO2001040464A1 (fr) Kinase 3 associee au recepteur de l'interleukine 1 (irak3) et son utilisation pour stimuler ou inhiber l'angiogenese et la cardiovascularisation
EP1112361A2 (fr) Promotion ou inhibition d'angiogenese et de cardiovascularisation
AU2003259607B2 (en) Promotion or inhibition of angiogenesis and cardiovascularization
EP1734051A2 (fr) Composition et procédés de diagnostic de tumeurs
ZA200103707B (en) Promotion or inhibition of angiogenesis and cardio-vascularization.
NZ540754A (en) Promotion or inhibition of angiogenesis and cardiovascularization
NZ545534A (en) Promotion or inhibition of angiogenesis and cardiovascularization
NZ535590A (en) Promotion or inhibition of angiogenesis and cardiovascularization
WO2001019987A1 (fr) Promotion ou inhibition de l'angiogenese et de la vascularisation cardiaque
NZ532803A (en) Promotion or inhibition of angiogenesis and cardiovascularization
ZA200105990B (en) Promotion or inhibition of angiogenesis and cardiovascularization.
CA2648046A1 (fr) Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued